Targeting homologous recombination repair defects in cancer.

@article{Evers2010TargetingHR,
  title={Targeting homologous recombination repair defects in cancer.},
  author={Bastiaan Evers and Thomas Helleday and Jos Jonkers},
  journal={Trends in pharmacological sciences},
  year={2010},
  volume={31 8},
  pages={
          372-80
        }
}
DNA repair is essential for cells to maintain genome stability in an environment that constantly produces DNA damage. There is a growing appreciation that defects in homologous recombination repair underlie hereditary and sporadic tumourigenesis, and that deficiency in this pathway may dictate the sensitivity of tumours to certain DNA-damaging agents. Homologous recombination deficiency (HRD) may therefore prove to be a diagnostic criterion per se if appropriate biomarkers become available to… CONTINUE READING
BETA

Figures, Tables, and Topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-10 OF 46 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 103 REFERENCES

A high-throughput pharmaceutical screen identifies compounds with specific toxicity against BRCA2-deficient tumors

  • B Evers
  • Clin. Cancer Res
  • 2010

Cancer predisposingmissense and protein truncating BARD1 mutations in non-BRCA1 or BRCA2 breast cancer families

  • S de Brakeleer
  • Hum. Mutat 31,
  • 2010

Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to poly(ADP-ribose) polymerase inhibitors

  • A Mukhopadhyay
  • Clin. Cancer Res
  • 2010

Efficacy of neoadjuvant Cisplatin in triplenegative breast cancer

  • Silver, D.P
  • J. Clin. Oncol
  • 2010

Mutation of the RAD51C gene in a Fanconi anemialike disorder

  • F Vaz
  • Nat. Genet
  • 2010

Similar Papers

Loading similar papers…